Is GT Biopharma Inc (GTBP) a Stock to Watch After Losing -9.09% This Week?

Tuesday, April 11, 2023 02:48 PM | InvestorsObserver Analysts

Mentioned in this article

Is GT Biopharma Inc (GTBP) a Stock to Watch After Losing -9.09% This Week?

Overall market sentiment has been down on GT Biopharma Inc (GTBP) stock lately. GTBP receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

GT Biopharma Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on GTBP!

See Full GTBP Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With GTBP Stock Today?

GT Biopharma Inc (GTBP) stock is trading at $0.50 as of 2:45 PM on Tuesday, Apr 11, an increase of $0.02, or 5.22% from the previous closing price of $0.48. The stock has traded between $0.48 and $0.54 so far today. Volume today is high. So far 288,274 shares have traded compared to average volume of 70,664 shares. To see InvestorsObserver's Sentiment Score for GT Biopharma Inc click here.

More About GT Biopharma Inc

GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. Click Here to get the full Stock Report for GT Biopharma Inc stock.